These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 30091061)

  • 61. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
    Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
    Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA;
    JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Plasma Low-Density Lipoprotein Cholesterol/High-Density Lipoprotein Cholesterol Concentration Ratio and Early Marker of Carotid Artery Atherosclerosis.
    Nimkuntod P; Tongdee P
    J Med Assoc Thai; 2015 May; 98 Suppl 4():S58-63. PubMed ID: 26201135
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia.
    Lam HC; Chu CH; Wei MC; Keng HM; Lu CC; Sun CC; Lee JK; Chuang MJ; Wang MC; Tai MH
    Exp Biol Med (Maywood); 2006 Jun; 231(6):1010-5. PubMed ID: 16741040
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Sillesen H; Amarenco P; Hennerici MG; Callahan A; Goldstein LB; Zivin J; Messig M; Welch KM;
    Stroke; 2008 Dec; 39(12):3297-302. PubMed ID: 18845807
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial.
    Ueshima K; Kasahara M; Koya D; Babazono T; Sato T; Imamoto M; Yasuno S; Fujimoto A; Tanaka S; Kimura G; Nakao K
    Clin Exp Nephrol; 2013 Apr; 17(2):211-7. PubMed ID: 22948416
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment.
    Stojakovic T; Claudel T; Putz-Bankuti C; Fauler G; Scharnagl H; Wagner M; Sourij H; Stauber RE; Winkler K; März W; Wascher TC; Trauner M
    Atherosclerosis; 2010 Mar; 209(1):178-83. PubMed ID: 19782361
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Beneficial effect of high dose statins on the vascular wall in patients with repaired aortic coarctation?
    Luijendijk P; Bouma BJ; Vriend JW; Groenink M; Vliegen HW; de Groot E; Pieper PG; van Dijk AP; Sieswerda GT; Konings TC; Stroes ES; Zwinderman AH; Mulder BJ
    Int J Cardiol; 2014 Sep; 176(1):40-7. PubMed ID: 25042661
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative studies on the effects of different doses of atorvastatin combined with aspirin on inflammatory cytokines and carotid plaques in patients with ischemic cerebrovascular disease.
    Deng Y; Zou W; Chen G; Shangguan S; Zhou F; Jiang W; Li X
    Int J Neurosci; 2019 Nov; 129(11):1133-1138. PubMed ID: 31232139
    [No Abstract]   [Full Text] [Related]  

  • 74. Association of Subclinical Hypothyroidism with Dyslipidemia and Increased Carotid Intima-Media Thickness in Children.
    Unal E; Akın A; Yıldırım R; Demir V; Yildiz İ; Haspolat YK
    J Clin Res Pediatr Endocrinol; 2017 Jun; 9(2):144-149. PubMed ID: 28008862
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Atorvastatin associated with gamma glutamyl transpeptidase elevation in a hyperlipidemia patient: A case report and literature review.
    Xu Y; Wu Y
    Medicine (Baltimore); 2020 Oct; 99(40):e22572. PubMed ID: 33019469
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.
    Gupta A; Thompson D; Whitehouse A; Collier T; Dahlof B; Poulter N; Collins R; Sever P;
    Lancet; 2017 Jun; 389(10088):2473-2481. PubMed ID: 28476288
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis.
    Kastelein JJ; van Leuven SI; Evans GW; Riley WA; Revkin JH; Shear CL; Bots ML;
    Curr Med Res Opin; 2007 Apr; 23(4):885-94. PubMed ID: 17407645
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia.
    Avis HJ; Hutten BA; Gagné C; Langslet G; McCrindle BW; Wiegman A; Hsia J; Kastelein JJ; Stein EA
    J Am Coll Cardiol; 2010 Mar; 55(11):1121-6. PubMed ID: 20223367
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison of alternate-day atorvastatin treatment to daily treatment in maintaining LDL-cholesterol targets in patients with variable coronary risk profile.
    Pattanaik S; Malhotra S; Sharma YP; Pandhi P
    J Cardiovasc Pharmacol; 2012 May; 59(5):479-84. PubMed ID: 22569288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.